Ajanta Pharma FY2026 Revenue Up 21%, PAT Rises 18%

Ajanta Pharma reported strong Q4 FY2026 results with revenue up 21% YoY to ₹1,422 crore and PAT up 18% to ₹267 crore.
Full-year consolidated revenue grew 17% to ₹5,453 crore while PAT increased 15% to ₹1,056 crore, with US generics segment surging 49%.
The company disclosed an ongoing income tax search from August 2025 and subsequent notice for block period 2019-2025 filing, with impact unascertainable.
Board approved audited standalone and consolidated financial results for year ended March 31, 2026, with unmodified audit opinion from BSR & Co. LLP.